Abstract | PURPOSE: Patients with castration-resistant prostate cancer (CRPC) receive second-generation androgen-deprivation therapy, but frequently experience relapse or do not respond. Understanding the genetic mechanisms of resistance will help to identify strategies and biomarkers that are essential for the next line of therapy. PATIENTS AND METHODS: RESULTS: CONCLUSION: CDK4/6-mediated resistance observed in preclinical experiments suggests that CDK4/6 amplifications may sufficiently promote enzalutamide resistance in CRPC, and that these patients may respond to palbociclib or ribociclib. The overall observations suggest that, in genomically selected advanced CRPC, clinical strategies against abiraterone- or enzalutamide-resistant tumors may require treatment strategies that are tailored to the resistance mechanisms that are specific to those patient subpopulations.
|
Authors | G Celine Han, Justin Hwang, Stephanie A M Wankowicz, Zhenwei Zhang, David Liu, Carrie Cibulskis, Glenn C Gaviola, Varand Ghazikhanian, Rana R McKay, Glenn J Bubley, Scott L Carter, Steven P Balk, William C Hahn, Mary-Ellen Taplin, Eliezer M Van Allen |
Journal | JCO precision oncology
(JCO Precis Oncol)
Vol. 1
( 2017)
ISSN: 2473-4284 [Electronic] United States |
PMID | 32913968
(Publication Type: Journal Article)
|
Copyright | © 2017 by American Society of Clinical Oncology. |